{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:18:14Z","timestamp":1790443094223,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"UCare Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.mayocp.2020.01.030","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T17:39:15Z","timestamp":1589996355000},"page":"1964-1977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Evidence-Based Pharmacotherapies for Alcohol Use Disorder"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-7010","authenticated-orcid":false,"given":"Jeremiah","family":"Fairbanks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Umbreit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6627-2410","authenticated-orcid":false,"given":"Bhanu Prakash","family":"Kolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Karpyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry D.","family":"Schneekloth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa L.","family":"Loukianova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirshendu","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2020.01.030_bib1","unstructured":"Trust for America's Health. Pain in the Nation. http:\/\/www.paininthenation.org. Accessed December 21, 2019."},{"issue":"8","key":"10.1016\/j.mayocp.2020.01.030_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III","volume":"72","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"10129","key":"10.1016\/j.mayocp.2020.01.030_bib3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk thresholds for alcohol consumption: combined analysis of individual participant data for 599 912 current drinkers in 83 prospective studies","volume":"391","author":"Wood","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2020.01.030_bib4","series-title":"Results From the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No (SMA) 14-4863","author":"Substance Abuse and Mental Health Services Administration","year":"2014"},{"issue":"5","key":"10.1016\/j.mayocp.2020.01.030_bib5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1017\/S0033291714002165","article-title":"The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies","volume":"45","author":"Verhulst","year":"2015","journal-title":"Psychol Med"},{"issue":"5387","key":"10.1016\/j.mayocp.2020.01.030_bib6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1126\/science.282.5387.298","article-title":"Transition from moderate to excessive drug intake: change in hedonic set point","volume":"282","author":"Ahmed","year":"1998","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.mayocp.2020.01.030_bib7","first-page":"185","article-title":"Neurobiology of alcohol dependence: focus on motivational mechanisms","volume":"31","author":"Gilpin","year":"2008","journal-title":"Alcohol Res Health"},{"key":"10.1016\/j.mayocp.2020.01.030_bib8","series-title":"Slaying The Dragon: the History of Addiction Treatment and Recovery in America","author":"White","year":"1998"},{"issue":"13","key":"10.1016\/j.mayocp.2020.01.030_bib9","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.284.13.1689","article-title":"Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation","volume":"284","author":"McLellan","year":"2000","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.mayocp.2020.01.030_bib11","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/jama.2018.16069","article-title":"Screening for unhealthy alcohol use","volume":"320","author":"Bazzi","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib12","doi-asserted-by":"crossref","first-page":"e20161210","DOI":"10.1542\/peds.2016-1211","article-title":"Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment","volume":"138","author":"Levy","year":"2016","journal-title":"Pediatrics"},{"issue":"18","key":"10.1016\/j.mayocp.2020.01.030_bib13","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1001\/jama.2018.12086","article-title":"Screening and behavioral counseling interventions in primary care to reduce unhealthy alcohol use in adolescents and adults: updated systematic review for the US Preventive Services Task Force","volume":"320","author":"O\u2019Connor","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2020.01.030_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"72","author":"Oslin","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0002-9378(79)90787-7","article-title":"Screening for alcohol-related problems in an outpatient obstetric-gynecologic clinic","volume":"134","author":"Russell","year":"1979","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.mayocp.2020.01.030_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0002-9378(89)90302-5","article-title":"The T-ACE questions: practical prenatal detection of risk-drinking","volume":"160","author":"Sokol","year":"1989","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.mayocp.2020.01.030_bib17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/sj.jp.7211266","article-title":"The 4P\u2019s Plus screen for substance use in pregnancy: clinical application and outcomes","volume":"25","author":"Chasnoff","year":"2005","journal-title":"J\u00a0Perinatol"},{"key":"10.1016\/j.mayocp.2020.01.030_bib18","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/sj.jp.7211823","article-title":"Validation of the 4P\u2019s Plus screen for substance use in pregnancy validation of the 4P\u2019s Plus","volume":"12","author":"Chasnoff","year":"2007","journal-title":"J Perinatol"},{"issue":"6","key":"10.1016\/j.mayocp.2020.01.030_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archpedi.153.6.591","article-title":"A\u00a0new brief screen for adolescent substance abuse","volume":"153","author":"Knight","year":"1999","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"10","key":"10.1016\/j.mayocp.2020.01.030_bib20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1046\/j.1532-5415.2002.50467.x","article-title":"The alcohol-related problems survey: identifying hazardous and harmful drinking in older primary care patients","volume":"50","author":"Fink","year":"2002","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.mayocp.2020.01.030_bib21","series-title":"\u201cAlcohol-use disorders: Diagnosis, assessment and management of harmful drinking and alcohol dependence.\u201d","year":"2011"},{"key":"10.1016\/j.mayocp.2020.01.030_bib22","series-title":"Clinical Manual of Addiction Psychopharmacology","first-page":"387","author":"Kranzler","year":"2014"},{"issue":"8","key":"10.1016\/j.mayocp.2020.01.030_bib23","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: a review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.mayocp.2020.01.030_bib24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMct0801733","article-title":"Naltrexone for the management of alcohol dependence","volume":"359","author":"Anton","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2020.01.030_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/oxfordjournals.alcalc.a008216","article-title":"Implications of endogenous opioid and dopamine in alcoholism: human and basic science studies","volume":"31","author":"Gianoulakis","year":"1996","journal-title":"Alcohol Alcohol"},{"issue":"18","key":"10.1016\/j.mayocp.2020.01.030_bib26","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.mayocp.2020.01.030_bib27","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","volume":"12","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2020.01.030_bib28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jsat.2007.05.011","article-title":"Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence","volume":"34","author":"Pettinati","year":"2008","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"11","key":"10.1016\/j.mayocp.2020.01.030_bib29","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.mayocp.2020.01.030_bib30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"10.1016\/j.mayocp.2020.01.030_bib31","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/acer.12197","article-title":"The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies","volume":"37","author":"Litten","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"10.1016\/j.mayocp.2020.01.030_bib32","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/acer.13410","article-title":"Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: a randomized pilot proof-of-concept study","volume":"41","author":"Busch","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"10.1016\/j.mayocp.2020.01.030_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0306-4603(96)00064-0","article-title":"Targeted naltrexone treatment of early problem drinkers","volume":"22","author":"Kranzler","year":"1997","journal-title":"Addict Behav"},{"issue":"13","key":"10.1016\/j.mayocp.2020.01.030_bib34","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"10118","key":"10.1016\/j.mayocp.2020.01.030_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2020.01.030_bib36","first-page":"CD001333","article-title":"Oral naltrexone maintenance treatment for opioid dependence","volume":"4","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.mayocp.2020.01.030_bib37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.jcp.0000084030.22282.6d","article-title":"Targeted naltrexone for early problem drinkers","volume":"23","author":"Kranzler","year":"2003","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.mayocp.2020.01.030_bib38","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study","volume":"31","author":"Karhuvaara","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"issue":"9","key":"10.1016\/j.mayocp.2020.01.030_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archpsyc.63.9.957","article-title":"Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment","volume":"63","author":"Krystal","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2004.03.004","article-title":"Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network","volume":"47","author":"Pierrefiche","year":"2004","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib41","first-page":"15","article-title":"Advances in medications and tailoring treatment for alcohol use disorder","volume":"37","author":"Seneviratne","year":"2015","journal-title":"Alcohol Res"},{"issue":"12","key":"10.1016\/j.mayocp.2020.01.030_bib42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","article-title":"Pharmacotherapy of alcoholism \u2014 an update on approved and off-label medications","volume":"18","author":"Soyka","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.mayocp.2020.01.030_bib43","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1038\/tp.2014.103","article-title":"Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate","volume":"4","author":"Karpyak","year":"2014","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.mayocp.2020.01.030_bib44","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","volume":"9","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.mayocp.2020.01.030_bib46","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate produces its anti-relapse effects via calcium","volume":"39","author":"Spanagel","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.mayocp.2020.01.030_bib47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","article-title":"The clinical pharmacology of acamprosate","volume":"77","author":"Kalk","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.mayocp.2020.01.030_bib48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1600-0773.1986.tb00114.x","article-title":"The mechanism of alcohol intolerance produced by various therapeutic agents","volume":"58","author":"Vasiliou","year":"1986","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0376-8716(98)00050-7","article-title":"Disulfiram effects on acute cocaine administration","volume":"52","author":"McCance-Katz","year":"1998","journal-title":"Drug Alcohol Depend"},{"issue":"23","key":"10.1016\/j.mayocp.2020.01.030_bib50","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.1980.03300490015010","article-title":"Disulfiram-like reaction to a cephalosporin","volume":"243","author":"McMahon","year":"1980","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.mayocp.2020.01.030_bib51","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism: a Veterans Administration cooperative study","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocp.2020.01.030_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00023210-200014050-00001","article-title":"Does disulfiram help to prevent relapse in alcohol abuse?","volume":"14","author":"Brewer","year":"2000","journal-title":"CNS Drugs"},{"key":"10.1016\/j.mayocp.2020.01.030_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1192\/bjp.161.1.84","article-title":"Disulfiram treatment of alcoholism","volume":"61","author":"Chick","year":"1992","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.mayocp.2020.01.030_bib54","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mayocp.2020.01.030_bib55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","article-title":"Safety issues concerning the use of disulfiram in treating alcohol dependence","volume":"20","author":"Chick","year":"1999","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.mayocp.2020.01.030_bib56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pbb.2008.02.009","article-title":"Effects of disulfiram and dopamine beta-hydroxylase knockout on cocaine-induced seizures","volume":"89","author":"Gaval-Cruz","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/clpt.1981.7","article-title":"Cardiovascular changes during the calcium carbamide-ethanol interaction","volume":"29","author":"Peachey","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.mayocp.2020.01.030_bib58","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM198111193052105","article-title":"Drug therapy: drugs to decrease alcohol consumption","volume":"305","author":"Sellers","year":"1981","journal-title":"N\u00a0Engl J Med"},{"issue":"9678","key":"10.1016\/j.mayocp.2020.01.030_bib59","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.mayocp.2020.01.030_bib60","first-page":"D000219","article-title":"Antibiotics for acute otitis media in children","volume":"1","author":"Glasziou","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocp.2020.01.030_bib61","first-page":"CD001841","article-title":"First-line drugs for hypertension","volume":"3","author":"Wright","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 5","key":"10.1016\/j.mayocp.2020.01.030_bib62","first-page":"S13","article-title":"Care of adults with type 2 diabetes mellitus. A review of the evidence","volume":"47","author":"O'Connor","year":"1998","journal-title":"J\u00a0Fam Pract"},{"issue":"45","key":"10.1016\/j.mayocp.2020.01.030_bib63","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.15585\/mmwr.mm6545a3","article-title":"CDC grand rounds: a public health approach to detect and control hypertension","volume":"65","author":"Merai","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.mayocp.2020.01.030_bib64","doi-asserted-by":"crossref","first-page":"e1001924","DOI":"10.1371\/journal.pmed.1001924","article-title":"Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials","volume":"12","author":"Palpacuer","year":"2015","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.mayocp.2020.01.030_bib65","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/add.13438","article-title":"Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers","volume":"111","author":"Fitzgerald","year":"2016","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.mayocp.2020.01.030_bib66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14740338.2015.1011619","article-title":"Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the phase III clinical programme","volume":"14","author":"van den Brink","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib67","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2005","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"10.1016\/j.mayocp.2020.01.030_bib68","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/1060028015585849","article-title":"The role of gabapentin in the management of alcohol withdrawal and dependence","volume":"49","author":"Leung","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2020.01.030_bib69","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin enacarbil extended-release for the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety","volume":"43","author":"Falk","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"10.1016\/j.mayocp.2020.01.030_bib70","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.mayocp.2020.01.030_bib71","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2014.13111526","article-title":"Potentiation of the effect of buprenorphine\/naloxone with gabapentin or quetiapine","volume":"171","author":"Reeves","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.mayocp.2020.01.030_bib72","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","article-title":"Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures","volume":"94","author":"Angehagen","year":"2005","journal-title":"J\u00a0Neurochem"},{"issue":"2","key":"10.1016\/j.mayocp.2020.01.030_bib73","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1124\/jpet.109.153908","article-title":"Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons","volume":"330","author":"Braga","year":"2009","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/B:NERE.0000010456.92887.3b","article-title":"Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons","volume":"29","author":"Poulsen","year":"2004","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib75","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.phrs.2011.03.004","article-title":"Topiramate modulation of beta(1)- and beta(3)-homomeric GABA(A) receptors","volume":"64","author":"Simeone","year":"2011","journal-title":"Pharmacolog Res"},{"issue":"14","key":"10.1016\/j.mayocp.2020.01.030_bib76","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: A randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mayocp.2020.01.030_bib77","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A\u00a0meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"issue":"9370","key":"10.1016\/j.mayocp.2020.01.030_bib78","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: A randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0000000000000246","article-title":"Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders","volume":"35","author":"Knapp","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib80","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugalcdep.2013.05.026","article-title":"A\u00a0double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence","volume":"133","author":"Kampman","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"10.1016\/j.mayocp.2020.01.030_bib81","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","article-title":"Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial","volume":"168","author":"Johnson","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mayocp.2020.01.030_bib82","series-title":"Trokendi XR [package insert]","year":"2013"},{"issue":"7","key":"10.1016\/j.mayocp.2020.01.030_bib83","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis","volume":"28","author":"Pierce","year":"2018","journal-title":"Eur Neuropsychopharm"},{"issue":"11","key":"10.1016\/j.mayocp.2020.01.030_bib84","first-page":"CD012557","article-title":"Baclofen for alcohol use disorder","volume":"11","author":"Minozzi","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2020.01.030_bib85","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0361-9230(98)00016-1","article-title":"Central 5-HT3 receptors in P and in AA alcohol-preferring rats: an autoradiographic study","volume":"46","author":"Ciccocioppo","year":"1998","journal-title":"Brain Res Bull"},{"issue":"7","key":"10.1016\/j.mayocp.2020.01.030_bib86","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/01.ALC.0000075547.77464.76","article-title":"Effects of ondansetron in early-versus late-onset\u00a0alcoholics: a prospective, open-label study","volume":"27","author":"Kranzler","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"issue":"8","key":"10.1016\/j.mayocp.2020.01.030_bib87","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jama.284.8.963","article-title":"Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2020.01.030_bib88","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.mayocp.2020.01.030_bib89","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/15504263.2018.1518553","article-title":"A\u00a0review of integrated care for concurrent disorders: cost effectiveness and clinical outcomes","volume":"15","author":"Karapareddy","year":"2019","journal-title":"J\u00a0Dual Diagn"},{"issue":"3","key":"10.1016\/j.mayocp.2020.01.030_bib90","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/1389201018666170224105025","article-title":"Personalized medicine of alcohol addiction: pharmacogenomics and beyond","volume":"18","author":"Ragia","year":"2017","journal-title":"Curr Pharm Biotecnol"},{"issue":"5","key":"10.1016\/j.mayocp.2020.01.030_bib91","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ajad.12463","article-title":"Pharmacogenetics of alcoholism treatment: implications of ethnic diversity","volume":"26","author":"Cservenka","year":"2017","journal-title":"Am J Addict"},{"issue":"13","key":"10.1016\/j.mayocp.2020.01.030_bib92","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1038\/npp.2017.74","article-title":"Predictors of naltrexone response in randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status","volume":"42","author":"Schacht","year":"2017","journal-title":"Neuropsychopharmacology"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619620300884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619620300884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:34:03Z","timestamp":1758418443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619620300884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0025619620300884"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.01.030","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-Based Pharmacotherapies for Alcohol Use Disorder","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}